Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institutes of Health Clinical Center (CC)
With
National Cancer Institute (NCI)
OBJECTIVES:
* Determine whether \[18F\]-labeled substance P antagonist receptor quantifier positron emission tomography can identify pancreatic cancer evident on multiphase CT scan.
OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than 15 days later, patients receive \[18F\]-labeled substance P antagonist receptor quantifier IV and undergo positron emission tomography over 6 hours.
Blood is collected periodically to measure the metabolism of the radiotracer by high performance liquid chromatography with radioactive detectors.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma of the pancreas
* Primary or metastatic disease
At least one site of measurable disease
Enrolled in an NCI protocol (either a treatment or screening protocol) such as NCI-05-C-0044 or NCI-05-C-0141
PATIENT CHARACTERISTICS:
ECOG performance status 0-2
WBC ≥ 1,200/mm³
Creatinine \< 2.0 mg/dL
Negative pregnancy test
Fertile patients must agree to use effective contraception
Not pregnant or nursing
More than 4 weeks since prior abdominal surgery
You may not be if
Allergy to IV contrast
Claustrophobia that would preclude completion of a scan or unable to lie on one's back for positron emission tomography scan
PRIOR CONCURRENT THERAPY:
Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits
Aprepitant within 72 hours of \[18F\]-labeled substance P antagonist receptor quantifier positron emission tomography